title: Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly.
abstract: BACKGROUND
  This study was designed to evaluate potential reversibility of left-ventricular (LV) dysfunction in patients with acromegaly following long-term control of disease. It is unknown whether the cardiac changes induced by acromegaly can be reversed completely by long-term strict control of growth hormone excess by octreotide.
  
  
  METHODS
  We compared LV systolic and diastolic function in inactive patients with acromegaly (n = 22), who were divided into patients with long-term control by octreotide (n = 14) and patients with long-term cure by surgery/radiotherapy (n = 8). We also assessed these parameters in patients with active acromegaly (n = 17).
  
  
  RESULTS
  In patients with active acromegaly, systolic function at rest was decreased by 18% (P < 0.01), LV mass index increased by 40% (P < 0.04) and isovolumetric relaxation time increased by 19% (P < 0.01), compared with patients with inactive acromegaly. These parameters were not different between well-controlled and cured patients. Using tissue Doppler imaging, the ratio between early and late diastolic velocity (E'/A' ratio) was decreased in active, compared with inactive acromegaly (0.75+/-0.07 versus 1.24+/-0.15; P < 0.01). This E'/A' ratio was considerably higher in cured, compared with octreotide-treated, patients (1.75+/-0.41 versus 1.05+/-0.1; P < 0.01).
  
  
  CONCLUSIONS
  Diastolic function is persistently and significantly more impaired in acromegalic patients with long-term control by octreotide than in surgically cured patients, which points to biological effects of subtle abnormalities in growth hormone secretion. Criteria for strict biochemical control of acromegaly should thus be reconsidered.
authors.affiliation: Department of Endocrinology and Metabolism, Leiden University Medical Center, The Netherlands.
authors.forename: S W
authors.initials: SW
authors.lastname: van Thiel
authors.forename: J J
authors.initials: JJ
authors.lastname: Bax
authors.forename: N R
authors.initials: NR
authors.lastname: Biermasz
authors.forename: E R
authors.initials: ER
authors.lastname: Holman
authors.forename: D
authors.initials: D
authors.lastname: Poldermans
authors.forename: F
authors.initials: F
authors.lastname: Roelfsema
authors.forename: H J
authors.initials: HJ
authors.lastname: Lamb
authors.forename: E E
authors.initials: EE
authors.lastname: van der Wall
authors.forename: J W A
authors.initials: JW
authors.lastname: Smit
authors.forename: J A
authors.initials: JA
authors.lastname: Romijn
authors.forename: A M
authors.initials: AM
authors.lastname: Pereira
mesh_terms: D000172:Acromegaly / Q000150:complications* / Q000188:drug therapy* / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D003971:Diastole; D015150:Echocardiography, Doppler; D005260:Female; D019382:Human Growth Hormone / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage*; D013599:Systole; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging / Q000209:etiology*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D019382:Human Growth Hormone; D015282:Octreotide